Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Trametes versicolor mushroom immune therapy in breast cancer.

Literature DB >> 19087769

Trametes versicolor mushroom immune therapy in breast cancer.

Leanna J Standish¹, Cynthia A Wenner, Erin S Sweet, Carly Bridge, Ana Nelson, Mark Martzen, Jeffrey Novack, Carolyn Torkelson.

Abstract

Data from multiple epidemiologic and clinical studies on immune effects of conventional cancer treatment and the clinical benefits of polysaccharide immune therapy suggest that immune function has a role in breast cancer prevention. Immune therapy utilizing the polysaccharide constituents of Trametes versicolor (Tv) as concurrent adjuvant cancer therapy may be warranted as part of a comprehensive cancer treatment and secondary prevention strategy.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 19087769 PMCID： PMC2845472

Source DB: PubMed Journal: J Soc Integr Oncol ISSN： 1715-894X

74 in total

1. Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan.

Authors: Shakeel Modak; Guenther Koehne; Andrew Vickers; Richard J O'Reilly; Nai-Kong V Cheung
Journal: Leuk Res Date: 2005-06 Impact factor: 3.156

2. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).

Authors: Yuji Ueda; Takashi Fujimura; Shinichi Kinami; Yasuo Hirono; Akio Yamaguchi; Hiroyuki Naitoh; Tohru Tani; Masahide Kaji; Hisakazu Yamagishi; Koichi Miwa
Journal: Jpn J Clin Oncol Date: 2006-06-27 Impact factor: 3.019

3. Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line.

Authors: A García-Lora; S Pedrinaci; F Garrido
Journal: Cancer Immunol Immunother Date: 2001-06 Impact factor: 6.968

4. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection.

Authors: Y Maehara; S Moriguchi; Y Sakaguchi; Y Emi; S Kohnoe; S Tsujitani; K Sugimachi
Journal: J Surg Oncol Date: 1990-11 Impact factor: 3.454

5. Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer.

Authors: Masahiko Shibata; Takeshi Nezu; Hisao Kanou; Yasuhiko Nagata; Tomo Kimura; Motoo Takekawa; Katsuyuki Ando; Masahiro Fukuzawa
Journal: Cancer Invest Date: 2002 Impact factor: 2.176

6. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer.

Authors: Y Iino; T Yokoe; M Maemura; J Horiguchi; H Takei; S Ohwada; Y Morishita
Journal: Anticancer Res Date: 1995 Nov-Dec Impact factor: 2.480

7. [Surgical treatment of Borrmann type 4 (diffuse) gastric cancer].

Authors: M Hirono; K Yoshinaka; K Matsuki; Y Noso; M Oride; T Toge; M Niimoto; T Hattori
Journal: Gan No Rinsho Date: 1984-05

8. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2.

Authors: Y Kariya; N Inoue; T Kihara; N Okamoto; K Sugie; T Mori; A Uchida
Journal: Immunol Lett Date: 1992-02-15 Impact factor: 3.685

9. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.

Authors: M Toi; T Hattori; M Akagi; K Inokuchi; K Orita; K Sugimachi; K Dohi; Y Nomura; Y Monden; Y Hamada
Journal: Cancer Date: 1992-11-15 Impact factor: 6.860

10. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.

Authors: Feng Hong; Richard D Hansen; Jun Yan; Daniel J Allendorf; Jarek T Baran; Gary R Ostroff; Gordon D Ross
Journal: Cancer Res Date: 2003-12-15 Impact factor: 12.701

15 in total

1. Trametes versicolor extract modifies human fecal microbiota composition in vitro.

Authors: Zhuo-Teng Yu; Bo Liu; Purna Mukherjee; David S Newburg
Journal: Plant Foods Hum Nutr Date: 2013-06 Impact factor: 3.921

2. Can we demonstrate that breast cancer "integrative oncology" is effective? A methodology to evaluate the effectiveness of integrative oncology offered in community clinics.

Authors: Leanna J Standish; Erin Sweet; Eleonora Naydis; M Robyn Andersen
Journal: Integr Cancer Ther Date: 2012-06-27 Impact factor: 3.279

10. Effect of Oral Supplementation of Biogenic Selenium Nanoparticles on White Blood Cell Profile of BALB/c Mice and Mice Exposed to X-ray Radiation.

Authors: Mohammad Hossein Yazdi; Maryam Masoudifar; Bardia Varastehmoradi; Ehsan Mohammadi; Erfan Kheradmand; Somayeh Homayouni; Ahmad Reza Shahverdi
Journal: Avicenna J Med Biotechnol Date: 2013-07

Trametes versicolor mushroom immune therapy in breast cancer.

1. Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan.

2. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).

3. Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line.

4. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection.

5. Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer.

6. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer.

7. [Surgical treatment of Borrmann type 4 (diffuse) gastric cancer].

8. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2.

9. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.

10. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.

1. Trametes versicolor extract modifies human fecal microbiota composition in vitro.

2. Can we demonstrate that breast cancer "integrative oncology" is effective? A methodology to evaluate the effectiveness of integrative oncology offered in community clinics.

Review 3. Historical and current perspectives on therapeutic potential of higher basidiomycetes: an overview.

4. A Hierarchy of Healing: Origins of the Therapeutic Order and Implications for Research.

5. Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer.

Review 6. Edible mushrooms: improving human health and promoting quality life.

7. Breast Cancer Integrative Oncology Care and Its Costs.

8. Recent developments in mushrooms as anti-cancer therapeutics: a review.

9. Antigenotoxic Effect of Trametes spp. Extracts against DNA Damage on Human Peripheral White Blood Cells.

10. Effect of Oral Supplementation of Biogenic Selenium Nanoparticles on White Blood Cell Profile of BALB/c Mice and Mice Exposed to X-ray Radiation.